Episode 36: Zavegepant and the Gepant Class for Migraine Care
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.
Episode 36 of the NeurologyLive
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 36, "Zavegepant and the Gepant Class for Migraine Care," features interviews with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven. The duo discusses how the investigational treatment fits into the gepant class and the impact that the gepants have had on migraine care overall.
EPISODE BREAKDOWN
1:40 – Stock on the background of this phase 2/3 clinical trial
4:15 – Shiovitz on zavegepant and its various formulations
5:25 – Stock on Biohaven's development of zavegepant
7:25 – Shiovitz on the gepant class in migraine
8:30 – Stock on the potential advantages of oral zavegepant
11:50 – Shiovitz on the takeaways for the clinical community
13:10 – Stock on Biohaven's goals in the migraine space
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
Perispinal Etanercept Shows No Efficacy in Treating Chronic StrokeSeptember 16th 2025
